heart disease – CFN Media

Positive Phase 2 Results Signal Promising Future For Cardiol Therapeutics

The future of smaller drug development companies frequently hinges on the results…

Robin Lefferts
June 20, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy…

Ryan Allway
June 13, 2024

Near-Term Catalysts on the Horizon for Cardiol Therapeutics

Investing in smaller drug development companies requires patience. The journey from discovery…

Robin Lefferts
May 28, 2024

Analyst and Research Coverage Bullish on Cardiol Therapeutics

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) has in some ways burst…

Robin Lefferts
May 1, 2024

The Impact of Positive Phase 2 Trial Results on a Smaller Company

A few weeks back, we covered the effect an Orphan Drug Designation…

Robin Lefferts
March 12, 2024

The Impact of Orphan Drug Development on a Smaller Company

Orphan drugs treat conditions with less than 200,000 patients annually in the…

Robin Lefferts
February 6, 2024

Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials

Any clinical trial program relies heavily on its administrators, advisors, and designers.…

Robin Lefferts
January 16, 2024

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

MAvERIC-Pilot is a Phase II Study in Recurrent Pericarditis and is Anticipated…

Ryan Allway
December 5, 2023

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Toronto, Ontario–(Newsfile Corp. – November 16, 2023) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

Ryan Allway
November 16, 2023

Simultaneous Clinical Trials by One Company Focused on Rare Heart Conditions

If you’ve been paying attention to the news in the last couple…

Robin Lefferts
October 26, 2023

Don Kreski

Robin Lefferts

Ryan Allway

Ryan has been a financial writer for more than a decade, covering…

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent…

Robin Lefferts
November 20, 2024

Aduro Clean Technologies Engages Global Leader Zeton for Design and Fabrication of Hydrochemolytic™ Pilot Plant

Milestone Project to Demonstrate Aduro’s Modular, Scalable Solution for Converting…

Ryan Allway
November 19, 2024

IKE Tech LLC and Ispire Technology Inc. Announce Positive Pre-PMTA Submission Meeting with the FDA

Seeks Authorization for Pioneering Point-of-Use Identity and Age Verification…

Ryan Allway
November 18, 2024

Healthcare Stocks

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained…

Ryan Allway
November 18, 2024